Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Precision BioSciences has raised $110 million in series B financing to advance a drug discovery program using Arcus, its homing endonuclease-based gene-editing tool. Homing endonucleases are enzymes, used by scientists years before CRISPR gene editing was invented, that recognize and cut DNA sequences. The Durham, N.C.-based firm will use the funds to move its lead therapy program, off-the-shelf CAR-T cancer treatments, into the clinic and begin field tests of crops edited with Arcus.
This article has been sent to the following recipient: